Illumina, Inc. (NASDAQ:ILMN)
| Market Cap | 40.51B+173.8% |
| Revenue (ttm) | 4.49B+4.9% |
| Net Income | 825.00M-34.4% |
| EPS | 5.36-32.2% |
| Shares Out | 151.30M |
| PE Ratio | 49.49 |
| Forward PE | 44.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,948,626 |
| Open | 271.61 |
| Previous Close | 273.54 |
| Day's Range | 260.45 - 276.20 |
| 52-Week Range | 88.00 - 309.35 |
| Beta | 1.42 |
| Analysts | Buy |
| Price Target | 241.00(-9.99%) |
| Earnings Date | Oct 29, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ILMN
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ILMN stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of ILMN by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Feb 10, 2026 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Feb 10, 2026 |
| Thomas H. KeanHouse / R | Purchase$1.00K – $15.00K | Apr 1, 2025 |
| Thomas KeanHouse / R | Purchase$1.00K – $15.00K | Apr 1, 2025 |
| Thomas KeanHouse / R | Purchase$1.00K – $15.00K | Mar 31, 2025 |
| Thomas H. KeanHouse / R | Purchase$1.00K – $15.00K | Apr 19, 2024 |
| Thomas KeanHouse / R | Purchase$1.00K – $15.00K | Apr 19, 2024 |
| Thomas KeanHouse / R | Purchase$1.00K – $15.00K | Apr 18, 2024 |
Recently reported changes in ILMN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ILMN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ILMN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ILMN Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Sequencing | $1.05B | 45.47% |
| Consumables | $852.00M | 36.76% |
| Service and other revenue | $177.00M | 7.64% |
| Instruments | $130.00M | 5.61% |
| Microarray | $105.00M | 4.53% |
As of: Q2 2026 (Jun 28, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ILMN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ILMN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ILMN
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $975.68M |
| VBVanguard Morningstar Small-Cap ETF | $706.60M |
| IVViShares Core S&P 500 ETF | $550.41M |
| SPYState Street SPDR S&P 500 ETF | $501.51M |
| VXFVanguard Extended Market ETF | $375.46M |
| IBBiShares Biotechnology ETF | $311.65M |
Estimated from each fund’s disclosed top holdings × AUM
ILMN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ILMN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score